Investigational drug · Phase 3
AD-227A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AD-227A"
First trial start
2024
Jul 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-227A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-227A" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227BPivotal-lookingRecruiting
Addpharma Inc.Industry
NCT06441630 · 251 participants (planned) · Start Jul 31, 2024 · Primary completion Sep 2025
Drug: AD-227A; AD-227B and 3 more · For: Essential Hypertension
Sites: Seoul, South Korea
Addpharma Inc.Industry
NCT06884085 · 70 participants · Start Jul 12, 2025 · Primary completion Aug 13, 2025
Drug: Co-administration of AD-227A and AD-227B; Administration of AD-227 · For: Primary Hypertension
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Essential Hypertension
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- Experimental: SacubitrilPhase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Essential Hypertension
- AD-227BPhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227CPhase 31 trial
Addpharma Inc. · Essential Hypertension
- ATB-1011Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1012Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1013Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.